MipSalus is a biotech company with leading-edge expertise in transforming Molecular Imprinted Polymers (MIPs) into a new class of medicines. MipSalus currently focuses on developing a breakthrough treatment of the rare and potentially invalidating disease Phenylketonuria (PKU) using phenylalanine-binding MIPs to block the uptake of dietary phenylalanine.
The name MipSalus is a combination of the abbreviation MIP – Molecular Imprinted Polymers – and Salus, the ancient Roman goddess of health and prosperity.
Recently, as a spin-off of the PKU drug project and using the Phe-binding MIPs, MipSalus has initiated development of a home sensor allowing PKU patients to monitor their disease and swiftly adjust food and medication.
MipSalus has facilities and laboratories in the research park Scion DTU, north of Copenhagen. To ensure optimal efficiency and flexibility, MipSalus is run by a lean core organization cooperating closely with research institutes, medical professionals, private subcontractors and others.
The company is owned by the founders and a group of private investors. In addition to funding from the owner group and co-funding from partners to joint projects, MipSalus has received grants from the Innovation Fund Denmark allowing MipSalus to accelerate the development of its drug candidate and the home sensor.
Building on its proprietary technology platform, MipSalus’ strategy is to identify and mature drug candidates and secure proof-of-concept before entering into partnerships for clinical development and commercialization.